Hangzhou-based cell therapy specialist ST Phi Therapeutics struck a partnership with US firm Azenta Life Sciences (NASDAQ: AZTA) to bolster the development of industrial cell pharmaceutical enterprises. No financial details were disclosed.
Company Background and Capabilities
Founded in 2018, ST Phi Therapeutics boasts its 3,600-square-meter GMP-compliant research and development center and manufacturing base. Azenta Life Sciences, meanwhile, provides comprehensive solutions covering every phase of cell and gene therapy (CGT) development.-Fineline Info & Tech
